ArticleVaccines2023

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.

Aleksandr V Kudriavtsev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.